Development of ceftazidime-avibactam...navigating an evolving regulatory environment

“Clinical development of ceftazidime-avibactam…Navigating an evolving regulatory environment”

David Melnick, M.D., Vice President Clinical Development, Anti-Infectives at Allergan Pharmaceuticals joined us for World Anti-Microbial Resistance Congress USA 2015 to discuss “navigating an evolving regulatory environment”.

In this presentation, learn about some of the effects of the changing regulatory environment on the clinical development of ceftazidime-avibactam.

Download the presentation to understand more about:

  • Avycaz
  • Carbapenem-resistant Enterobacteriaceae (CRE)
  • Well-defined PK/PD targets

..and much more!

Get your copy here!

To learn more about navigating an evolving regulatory environment, join us at World Anti-Microbial Resistance Congress USA 2016 held September 8-9 in Washington, DC!

Attend World Anti-Microbial Resistance USA 2016

Leave a Reply

Your email address will not be published. Required fields are marked *